Noelia Purroy

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

Courtney DiNardo, Eduardo Rodríguez‐Arbolí, Jordi Esteve, Olga Salamero et autres

us, es, se, be (code pays fourni par la source)

91 | BMS‐986458, A FIRST‐IN‐CLASS, BIFUNCTIONAL CEREBLON‐DEPENDENT LIGAND‐DIRECTED DEGRADER (LDD) OF B‐CELL LYMPHOMA 6 (BCL6) IN PATIENTS WITH R/R NHL: INITIAL PH 1 RESULTS

F. Morschhauser, David Qualls, Jennifer Kimberly Lue, Anastasios Stathis et autres

fr, us, ch, nl, de, es (code pays fourni par la source)

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie X. Peng, Rama Krishna Narla, Joshua M. Baughman et autres

us (code pays fourni par la source)

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, José Francisco Juárez López, Estela Garcia, Alejandro Panjkovich et autres

us (code pays fourni par la source)

ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Erin M. Parry, Camilla K. Lemvigh, Stephanie Deng, Nathan Dangle et autres

us, dk, fr, au (code pays fourni par la source)

Data from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Figure S1 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Table S2 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Table S2 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Figure S4 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Figure S5 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres

Figure S3 from Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

Helene Kretzmer, Anat Biran, Noelia Purroy, Camilla K. Lemvigh et autres